TY - JOUR T1 - Epidemiological and clinical characteristics, and response to treatment in 113 patients with microscopic colitis JO - Gastroenterología y Hepatología (English Edition) T2 - AU - Rojo,Eukene AU - Casanova,María José AU - Gisbert,Javier P. SN - 24443824 M3 - 10.1016/j.gastre.2021.10.002 DO - 10.1016/j.gastre.2021.10.002 UR - https://www.elsevier.es/en-revista-gastroenterologia-hepatologia-english-edition--382-articulo-epidemiological-clinical-characteristics-response-treatment-S2444382421002297 AB - ObjectiveTo study the epidemiological and clinical characteristics, and response to treatmentin patients with microscopic colitis. Patients and methodEpidemiological, clinical, blood test and endoscopic data were retrospectively collected from 113 patients with microscopic colitis. Response to treatment was analyzed in 104 of them. Efficacy and relapse after treatment with budesonide were assessed using survival curves (Kaplan-Meier). Results78% of the patients were women, with a mean age of 65 ± 16 years. In smokers, the mean age was 10 years younger. 48% of them had some concomitant autoimmune disease; 60% suffered a single outbreak of the disease. The clinical presentation was similar in both subtypes, although patients with collagenous colitis had a chronic course more frequently (48% vs. 29%, P = .047). The remission rate with budesonide was 93% (95% CI 82–98). The cumulative incidence of relapse, after a median follow-up of 21 months, was 39% (95% CI 26%–54%): 19% at one year, 32% at two years, and 46% at three years of follow-up. There were no differences in clinical response to budesonide based on smoking habit or microscopic colitis subtype. ConclusionsMicroscopic colitis is more frequent in elderly women. Smoking was associated with earlier onset of the disease, although it did not influence the clinical course or response to treatment. The majority (>90%) of patients treated with budesonide achieved remission, although nearly half subsequently relapsed. ER -